Child-Pugh Classification
Severity of cirrhosis from encephalopathy, ascites, bilirubin, albumin and INR
5 items left
Cautions
- An index of the severity of cirrhosis. Five components are scored 1 to 3 points each and added (total 5 to 15) to give class A, B or C
- The FDA guidance names the subjective assessment of ascites as a limitation of the classification
- The FDA guidance (written for studies of drug dosing in hepatic impairment) cautions that bilirubin, INR and albumin can change for reasons unrelated to liver function, for example vitamin K deficiency or anticoagulants (INR), Gilbert’s syndrome (bilirubin) and intravenous fluids (albumin). It advises checking that a change is due to the liver disease, and it advises against scoring during or shortly after an acute event, because a higher score may not reflect the baseline
- Some tables give different bilirubin points in primary biliary cholangitis (PBC). The MSD Manual calculator (EBMcalc) gives 1 point for 1 to 4 mg/dL, 2 points for 4 to 10 mg/dL and 3 points for more than 10 mg/dL, and it does not say where exactly 4 falls. The FDA table has no such cut-offs and this screen does not apply them, so in PBC the bilirubin points here may be higher than in those tables (for example 5 mg/dL scores 3 points here and 2 points there), which can change the class
- The Japanese cirrhosis guideline 2020 (in Japanese) lists among the problems of this classification: subjective and objective factors are mixed, the five factors are added with equal weight, and bilirubin of 3.0 mg/dL or more and albumin under 2.8 g/dL are lumped into one category, so it is poorly suited to telling apart the most severe patients; on this screen, a bilirubin of exactly 3.0 mg/dL scores 2 points
- This screen scores the INR. The FDA table lists prothrombin time as seconds prolonged as an alternative; a prothrombin time activity in percent is not used
References
- Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60(8):646-649. (original not seen) PMID: 4541913, DOI: 10.1002/bjs.1800600817[Original article]
- Japanese Society of Gastroenterology and Japan Society of Hepatology, ed. Evidence-based Clinical Practice Guidelines for Liver Cirrhosis 2020, 3rd revised edition (in Japanese; English title translated by the authors of this site). Tokyo: Nankodo; 2020. (Chapter 5, BQ 5-1 (explanation of the problems of the Child-Pugh classification)) https://www.jsge.or.jp/committees/guideline/guideline/pdf/kankouhen2020_re.pdf[Guideline]
- EBMcalc. Child Pugh Classification for Severity of Liver Disease. MSD Manuals, medical calculators (copyright 1998-2018 Foundation Internet Services). (Note on primary biliary cirrhosis and its bilirubin points) https://www.msdmanuals.com/en-gb/medical-calculators/ChildTurPuScore.htm[Review article]
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage. Guidance for Industry (draft). September 2026. (Section IV.A.1 (Child-Pugh Classification), Table 1) https://www.fda.gov/media/71311/download[Guideline]
Checked on: 2026-11-07
Disclaimer
This calculation is intended to support the judgment of healthcare professionals. Results are for reference only; decisions about diagnosis and treatment must be made by the responsible healthcare professional. The values you enter never leave your device.